AI Analysis | Feedback

• A **Teladoc Health** for personalized, AI-driven chronic condition management (diabetes, hypertension, MSK).
• Like **Noom**, but for managing multiple serious chronic conditions (diabetes, hypertension, MSK) with an AI-powered platform and personalized coaching.
• A digital, AI-enhanced **Weight Watchers (WW)** program for a wide range of chronic health conditions beyond just weight management.

AI Analysis | Feedback

• Dario Chronic Condition Management Platform: A comprehensive digital health platform offering personalized coaching, real-time insights, and connected devices to help individuals manage multiple chronic health conditions.
• Diabetes Management Program: A digital program providing connected blood glucose monitoring, personalized coaching, and educational resources for individuals with diabetes.
• Hypertension Management Program: A digital program featuring connected blood pressure monitoring, personalized coaching, and lifestyle guidance for individuals managing high blood pressure.
• Weight Management Program: A digital program that includes connected smart scales, personalized coaching, and nutritional guidance to support healthy weight loss and maintenance.
• Behavioral Health Program: A digital program providing access to mental health coaching, licensed therapists, and self-guided tools to support mental well-being and address behavioral health challenges.

AI Analysis | Feedback

DarioHealth (DRIO) primarily sells its digital health solutions to other companies, rather than directly to individuals. According to DarioHealth's public filings (such as their annual 10-K reports), the company states that it has a diverse customer base and does not depend on any single customer for a material portion of its revenue. Therefore, no individual company is publicly identified as a "major customer" accounting for a significant percentage of their overall revenue.

Instead, DarioHealth's customer base is comprised of various organizations across key segments within the healthcare ecosystem. These major customer categories, which represent the types of companies DarioHealth sells to, include:

• Health Plans and Payers: These are insurance companies, self-funded employers, and other entities that provide health benefits. They contract with DarioHealth to offer its digital therapeutics platform to their members or beneficiaries as a covered benefit.
• Employers: Companies directly contract with DarioHealth to provide DarioHealth's chronic condition management programs to their employees as part of their corporate wellness or benefits programs.
• Strategic Partners: This category includes a variety of entities such as benefits consultants, pharmacy benefit managers (PBMs), other healthcare technology providers, and healthcare systems that either resell DarioHealth's solutions or integrate them into broader service offerings.

While DarioHealth does not disclose the names of specific individual customer companies within these categories due to the distributed nature of its client base and confidentiality agreements, these represent the primary types of organizations that purchase and utilize DarioHealth's services.

AI Analysis | Feedback

AI Analysis | Feedback

Erez Raphael, Chief Executive Officer

Erez Raphael has served as the CEO and a Director of DarioHealth since August 2013. He is also a co-founder of DarioHealth. Mr. Raphael possesses over 17 years of experience in the software industry, with expertise spanning software development, product management, and software portfolio management. He co-founded redB LTD in early 2011, which launched mySuper.co.il, a prominent e-commerce platform for supermarkets in Israel. Prior to becoming CEO, he was DarioHealth's VP Product and R&D, and he has held leadership roles at Amdocs and Nokia Siemens Networks.

Chen Franco-Yehuda, Chief Financial Officer, Treasurer, and Secretary

Chen Franco-Yehuda assumed the role of Chief Financial Officer, Treasurer, and Secretary at DarioHealth on May 15, 2025. She brings extensive financial leadership experience, particularly within the healthcare and life sciences sectors. Previously, she served as CFO, Treasurer, and Secretary at Pluri Inc., a global biotech company. In this role, she was responsible for financial strategy, investor relations, legal affairs, and significant cross-border transactions, including securing substantial capital through various fundraising rounds and driving merger and acquisition activities. Ms. Franco-Yehuda was honored with the Israeli CFO Excellence Award in January 2025. Her career began as an Audit/Assurance Manager at PwC, and she is a licensed CPA in Israel.

Rick Anderson, President & General Manager, North America

Rick Anderson joined DarioHealth as President and General Manager of North America from Catasys, Inc. (later OnTrak, Inc.), where he spent nearly 12 years. At Catasys, he served as President, Chief Operating Officer, and a board member, building and scaling the business to tens of millions in recurring revenue and securing agreements with major U.S. health plans. He led Catasys from its conceptual stage to an approximate $500 million market capitalization. His prior experience includes being a Senior Executive Vice President at Hythiam, Inc., a predecessor to Catasys, Inc. Mr. Anderson also held the position of Chief Financial Officer and Secretary at Clearant, Inc., a biotechnology company, and was CFO and Managing Director of Intellect Capital Group, a venture consulting firm.

Omar Manejwala, M.D., Chief Medical Officer

Dr. Omar Manejwala is recognized as a leading expert in behavior change, with a career focused on developing, piloting, and commercializing scalable solutions that promote durable behavior change in chronic diseases. Before joining DarioHealth, he served as the Chief Medical Officer of Catasys Inc. At Catasys, he was instrumental in leading product development from inception to commercial scale, securing contracts with many of the largest U.S. health plans, and contributing to the company's growth to an approximate $1.5 billion valuation at its peak. Dr. Manejwala is a Distinguished Fellow of the American Psychiatric Association, a Fellow of the American Society of Addiction Medicine, and the author of the best-selling book "Craving: Why We Can't Seem to Get Enough."

Steven Nelson, President & Chief Commercial Officer

Steven Nelson is responsible for developing and executing strategies to drive rapid commercialization at DarioHealth, overseeing global commercial activities including growth strategy, sales, client management, marketing, strategic partnerships, and market expansion. He possesses over two decades of experience in building and scaling technology-centric healthcare companies. Most recently, Mr. Nelson was the Chief Executive Officer and President of Contigo Health, where he successfully scaled the company's revenue, achieved profitability, managed over 75 clients, and established numerous national and regional health plan and employer partnerships.

AI Analysis | Feedback

The key risks to DarioHealth's (DRIO) business are primarily centered around its financial viability, intense market competition, and the evolving regulatory and operational landscape.

1. Financial Stability and Going Concern: DarioHealth has reported significant operating losses and an accumulated deficit, reaching approximately $390.3 million as of December 31, 2024. The company has not yet achieved profitability. Management has disclosed substantial doubt about DarioHealth's ability to continue as a going concern, indicating that current cash resources are insufficient for a full year of operations. The company also faced a breach of a financial covenant under a credit agreement as of June 30, 2025, with a waiver granted conditional on an equity cure by November 15, 2025.
2. Market Competition and Revenue Challenges: The digital health market in which DarioHealth operates is highly competitive, making it challenging for the company to secure and maintain a substantial market share. Analysts have downgraded revenue estimates for DarioHealth, projecting slower revenue growth compared to the broader industry. The company's ability to expand its customer base and enhance its digital health engagement platform is crucial for market penetration and revenue growth.
3. Regulatory Compliance and Customer Concentration: DarioHealth must navigate a complex and evolving regulatory environment to obtain and maintain marketing authorizations for its products. This includes complying with cybersecurity requirements for medical devices, which can lead to increased costs and operational hurdles. Additionally, the company faces operational risks due to a degree of customer concentration; as of December 31, 2024, one major customer accounted for 41.6% of accounts receivable, although this percentage decreased to 16.4% by June 30, 2025. The loss of a significant customer could materially impact revenue.

AI Analysis | Feedback

There are two clear emerging threats for DarioHealth:

1. Entry and Expansion of Large Technology Companies: Major tech players like Amazon, Google, and Apple are increasingly entering and expanding their presence in the healthcare and digital health sectors. Amazon, with its Amazon Clinic and Amazon Pharmacy, shows a clear intent to provide integrated healthcare services. Should these companies leverage their vast resources, existing customer bases, and technological prowess to offer comprehensive chronic condition management platforms (potentially bundling devices, coaching, and virtual care at scale), they could significantly disrupt or marginalize specialized digital health providers like DarioHealth. This mirrors the historical threat posed by new, powerful entrants with broad ecosystems.

2. Market Consolidation and Demand for Integrated Platforms: The digital health market is undergoing significant consolidation, with employers and health plans increasingly prioritizing integrated, multi-condition platforms over fragmented point solutions. The merger of Teladoc and Livongo is a prime example of this trend, creating a more comprehensive virtual care and chronic condition management offering. This trend puts pressure on companies like DarioHealth to compete against larger, more integrated platforms that can offer a broader suite of services under a single vendor, potentially leading to increased competition for partnerships and market share.

AI Analysis | Feedback

DarioHealth Addressable Markets

• Digital Therapeutics (Overall): The global addressable market for digital therapeutics is approximately $108 billion. In the U.S. alone, this market is estimated at $72 billion annually.
• Diabetes Management:
  • The U.S. diabetes market for monitoring, treatment, and drug delivery was valued at nearly $48 billion in 2024 and is projected to reach $79 billion by 2031.
  • The U.S. digital diabetes management market size was valued at $3.92 billion in 2024 and is expected to reach $17.23 billion by 2033.
  • The U.S. diabetes devices market was valued at $9.53 billion in 2023 and is expected to reach $15.21 billion by 2030.
  • The North America diabetes care industry is estimated at $34.51 billion in 2025 and is expected to reach $62.73 billion by 2032.
• Hypertension Management:
  • The U.S. pain management market, which includes musculoskeletal pain, was valued at $31.80 billion in 2024 and is estimated to reach $32.79 billion in 2025, projected to grow to $43.58 billion by 2033.
  • North America held a major share of the global Hypertension Management Devices market, with a market size of $2.073 billion in 2024. The U.S. alone had a market size of $1.6356 billion in 2024 for hypertension management devices.
  • The global antihypertensive drugs market is forecast to grow from $25.50 billion in 2025 to $35.99 billion by 2034. North America dominated this market with a 38% revenue share in 2024.
• Weight Management:
  • The U.S. weight loss and obesity management market size is likely to be valued at $5.5 billion in 2025 and is expected to reach $7.5 billion by 2032.
  • The U.S. weight management market size was estimated at $37.86 billion in 2023 and is expected to grow to $76.9 billion by 2030.
  • The global weight management market size is calculated at $163.13 billion in 2024 and is expected to be worth $362.1 billion by 2034. North America led the global weight management market in 2024 with a revenue of $84.5 billion.
• Musculoskeletal (MSK) Health:
  • The U.S. pain management market was valued at $31.80 billion in 2024 and is estimated to reach $32.79 billion in 2025, projected to grow to $43.58 billion by 2033. The musculoskeletal pain segment held 41.2% of the U.S. pain management market share in 2024.
  • The global musculoskeletal disorders treatment market is anticipated to grow from $209.01 billion in 2025 to $353.12 billion by 2034. North America reported being the largest region with a 37% market share in 2023.
  • The musculoskeletal pain market across the top 7 markets (US, EU4, UK, and Japan) reached a value of $4.0878 billion in 2024 and is expected to reach $5.7579 billion by 2035. The United States has the largest patient pool for musculoskeletal pain and also represents the largest market for its treatment.
• Behavioral/Mental Health:
  • The U.S. behavioral health market size was valued at $92.2 billion in 2024, is expected to reach $96.9 billion in 2025, and is projected to hit $151.62 billion by 2034.
  • Another estimate values the U.S. mental health market size at $110 billion in 2024, expected to reach $132 billion by 2033.
  • The U.S. behavioral health market size was valued at $87.82 billion in 2024. It is projected to grow from $92.14 billion in 2025 to $132.46 billion by 2032.
  • The North America behavioral health market size is calculated at $109.21 billion in 2024, grew to $115.65 billion in 2025, and is projected to reach around $193.03 billion by 2034.

AI Analysis | Feedback

AI Analysis | Feedback

Share Issuance

• In February 2021, DarioHealth closed a registered direct offering of 3,278,688 shares of common stock at a purchase price of $21.35 per share, generating aggregate gross proceeds of $70,000,000.
• In late 2024 and early 2025, the company completed a $25.6 million private placement of convertible preferred stock.
• By the end of Q2 2025, DarioHealth completed an oversubscribed $17.5 million private placement, increasing its pro forma cash position to approximately $40 million.

Inbound Investments

• DarioHealth completed a $25.6 million private placement of convertible preferred stock in late 2024 and early 2025, with significant participation from existing shareholders and accredited healthcare investors.
• In September 2025, the company completed an oversubscribed $17.5 million private placement.

Outbound Investments

• DarioHealth acquired Upright for $31 million in January 2021.
• In May 2021, the company acquired wayForward for aggregate consideration of $6.0 million in cash and up to $24.0 million in shares of common stock.
• DarioHealth acquired Twill for $10 million in February 2024.

Capital Expenditures

• In the last 12 months as of October 2025, DarioHealth reported capital expenditures of approximately $128,000.